Home Healthcare Pharmaceuticals Pneumonia Therapeutics Market

Pneumonia Therapeutics Market Size, Share & Trends Analysis Report By Product Type (Drugs, Vaccine, Oxygen Therapy), By Infection (Hospital-acquired Pneumonia (HAP), Community-acquired Pneumonia (CAP), Ventilator-associated Pneumonia (VAP)), By Route of Administration (Oral, Parenteral, Other Routes of Administration), By End Use (Hospitals, Homecare, Specialty Clinics, Other End Uses) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 06, 2026 | Author: Debashree B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Pneumonia Therapeutics Market, By Product Type 2022-2034 (USD MILLION/ Units)
    1. Drugs
    2. Vaccine
    3. Oxygen Therapy
  2. Pneumonia Therapeutics Market, By Infection 2022-2034 (USD MILLION/ Units)
    1. Hospital-acquired Pneumonia (HAP)
    2. Community-acquired Pneumonia (CAP)
    3. Ventilator-associated Pneumonia (VAP)
  3. Pneumonia Therapeutics Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Parenteral
    3. Other Routes of Administration
  4. Pneumonia Therapeutics Market, By End Use 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Homecare
    3. Specialty Clinics
    4. Other End Uses
  5. Regional Pneumonia Therapeutics Market
    1. North America
      1. North America Pneumonia Therapeutics Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
      2. North America Pneumonia Therapeutics Market By Infection 2022-2034 (USD MILLION/ Units)
        1. Hospital-acquired Pneumonia (HAP)
        2. Community-acquired Pneumonia (CAP)
        3. Ventilator-associated Pneumonia (VAP)
      3. North America Pneumonia Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Other Routes of Administration
      4. North America Pneumonia Therapeutics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Other End Uses
      5. U.S.
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      6. Canada
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
    2. Europe
      1. Europe Pneumonia Therapeutics Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
      2. Europe Pneumonia Therapeutics Market By Infection 2022-2034 (USD MILLION/ Units)
        1. Hospital-acquired Pneumonia (HAP)
        2. Community-acquired Pneumonia (CAP)
        3. Ventilator-associated Pneumonia (VAP)
      3. Europe Pneumonia Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Other Routes of Administration
      4. Europe Pneumonia Therapeutics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Other End Uses
      5. U.K.
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      6. Germany
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      7. France
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      8. Spain
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      9. Italy
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      10. Russia
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      11. Nordic
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      12. Benelux
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      13. Rest of Europe
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
    3. APAC
      1. APAC Pneumonia Therapeutics Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
      2. APAC Pneumonia Therapeutics Market By Infection 2022-2034 (USD MILLION/ Units)
        1. Hospital-acquired Pneumonia (HAP)
        2. Community-acquired Pneumonia (CAP)
        3. Ventilator-associated Pneumonia (VAP)
      3. APAC Pneumonia Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Other Routes of Administration
      4. APAC Pneumonia Therapeutics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Other End Uses
      5. China
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      6. Korea
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      7. Japan
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      8. India
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      9. Australia
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      10. Taiwan
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      11. South East Asia
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      12. Rest of Asia-Pacific
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
    4. Middle East and Africa
      1. Middle East and Africa Pneumonia Therapeutics Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
      2. Middle East and Africa Pneumonia Therapeutics Market By Infection 2022-2034 (USD MILLION/ Units)
        1. Hospital-acquired Pneumonia (HAP)
        2. Community-acquired Pneumonia (CAP)
        3. Ventilator-associated Pneumonia (VAP)
      3. Middle East and Africa Pneumonia Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Other Routes of Administration
      4. Middle East and Africa Pneumonia Therapeutics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Other End Uses
      5. UAE
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      6. Turkey
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      7. Saudi Arabia
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      8. South Africa
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      9. Egypt
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      10. Nigeria
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      11. Rest of MEA
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
    5. LATAM
      1. LATAM Pneumonia Therapeutics Market By Product Type 2022-2034 (USD MILLION/ Units)
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
      2. LATAM Pneumonia Therapeutics Market By Infection 2022-2034 (USD MILLION/ Units)
        1. Hospital-acquired Pneumonia (HAP)
        2. Community-acquired Pneumonia (CAP)
        3. Ventilator-associated Pneumonia (VAP)
      3. LATAM Pneumonia Therapeutics Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Parenteral
        3. Other Routes of Administration
      4. LATAM Pneumonia Therapeutics Market By End Use 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Other End Uses
      5. Brazil
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      6. Mexico
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      7. Argentina
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      8. Chile
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      9. Colombia
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
      10. Rest of LATAM
        1. Drugs
        2. Vaccine
        3. Oxygen Therapy
        4. Hospital-acquired Pneumonia (HAP)
        5. Community-acquired Pneumonia (CAP)
        6. Ventilator-associated Pneumonia (VAP)
        7. Oral
        8. Parenteral
        9. Other Routes of Administration
        10. Hospitals
        11. Homecare
        12. Specialty Clinics
        13. Other End Uses
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.